New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona, Verona, Italy; 3Allergy & Respiratory Di...
Enregistré dans:
Auteurs principaux: | Caminati M, Bagnasco D, Vaia R, Senna G |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/94f3d5e54f2e44f0bbf5750e6f077a31 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
par: John Davison, et autres
Publié: (2021) -
Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
par: Kawabata H, et autres
Publié: (2021) -
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
par: Haldar P
Publié: (2017) -
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
par: Angelantonio Maglio, et autres
Publié: (2021) -
Characterizing Inflammatory Cell Asthma Associated Phenotypes in Dental Health Workers Using Cytokine Profiling
par: Tanusha Singh, et autres
Publié: (2021)